Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 238-247

  Thompson, John F ^a,b   Kam, Peter C A ^a,b   Waugh, Richard C ^a   Harman, C Richard ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anoxia; Antineoplastic agents; Induced hyperthermia; Intra arterial infusions; Melanoma; Melphalan; Regional perfusion; Remission induction; Sarcoma; Tumor necrosis factor

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CYTOPATHOGENIC EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTHERMIC THERAPY; HYPOXIC CELL; LIMB PERFUSION; MELANOMA; PRIORITY JOURNAL; REGIONAL PERFUSION; SARCOMA; SKIN TOXICITY;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERIZATION, PERIPHERAL; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACTINOMYCIN; EXTREMITIES; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MELANOMA; MELPHALAN; SKIN NEOPLASMS; TOURNIQUETS;

EID: 0031893171     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<238::AID-SSU8>3.0.CO;2-9     Document Type: Article

References (38)

1. Vrouenraets BC, Nieweg OE, Kroon BB: Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319-1328.
2. Thompson JF, Hunt JA, Shannon KF, Kam PC: Frequency and duration of remission after isolated limb perfusion. Arch Surg 1997;132:903-907.
3. Lienard D, Eggermont AM, Schraffordt Koops H, et al: Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994;4(Suppl 1):21-26.
4. Creech OJ, Krementz ET, Ryan RF, Winblad JN: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-632.
5. Karakousis CP, Kanter PM, Lopez R, et al: Modes of regional chemotherapy. J Surg Res 1979;26:134-141.
6. Karakousis C, Kanter PM, Park HC, et al: Tourniquet infusion versus hyperthermic perfusion. Cancer 1982;49:850-858.
7. Bland KI, Kimura AK, Brenner DE, et al: A phase II study of the efficacy of diamminedichloroplatinum (Cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 1989;209:73-80.
8. Thompson JF, Waugh RC, Saw RP, Kam PC: Isolated limb infusion (ILI) with melphalan for recurrent limb melanoma. Reg Cancer Treat 1993;6:51-52.
9. Thompson JF, Waugh RC, Saw RP, Kam PC: Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994;7:188-192.
10. Thompson JF, Kam PC, Saw RP, et al: Isolated limb infusion for melanoma: Results of an elective double infusion protocol. Reg Cancer Treat 1995;8:122-127.
11. Wieberdink J, Benckhuijsen C, Braat RP: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
12. Thompson JF, Lai DT, Ingvar C, Kam PC: Isolated limb perfusion for melanoma: maximising efficacy and minimising toxicity. Melanoma Res 1994;4(Suppl 1):45-50.
13. Lai DT, Ingvar C, Thompson JF: The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993;6:36-39.
14. Thompson JF, Malouf DJ, Merzliakov S, Kam PC: Efficacy of single-dose ondansentron in the prevention of post-operative nausea and vomiting following isolated limb perfusion with cytotoxic agents. Reg Cancer Treat 1993;4:177-182.
15. Thompson JF, Good PD, Kam PC: Hypethermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat 1994;7:147-154.
16. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992;16:227-233.
17. Teacher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81.
18. van de Merwe SA, van den Berg AP, Kroon BB, et al: Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperther 1993;9:205-217.
19. Chaplin DJ, Acker B, Oliver PL: Potentiation of the tumour cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phy 1989;16:1131-1135.
20. Siemann DW, Chapman M, Biekirch A: Effects of oxygenation and pH on tumor cell response to alkylatins chemotherapy. Int J Radiat Oncol Biol Phys 1991;20:287-289.
21. Skarsgard LD, Skwarchuk MW, Vinczan A, et al: The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995;15:219-224.
22. Stratford IJ, Adams GE, Godden J, et al: Potentiation of anti-tumour effect of melphalan by the vasoactive agent, hydralazine. Br J Cancer 1988;58:122-124.
23. Aigner KR: Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis - rationale and technique. Reg Cancer Treat 1993;6(Suppl 1):3.
24. Aigner KR, Kaevel K: Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer Treat 1994;7:6-11.
25. Thompson JF, Liu M, Waugh RC, et al: A percutaneous aortic "stopflow" infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat 1994;7:202-207.
26. Cavaliere R, Ciocatto EC, Giovanella BC, et al: Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 1967;20:1351-1381.
27. Kroon BB: Regional isolated perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol 1988;14:101-110.
28. Thompson JF, Kam PC, Ramzan I, Yau DF: Clinical pharmacokinetics of melphalan in isolated limb perfusion: compartmental modelling and moment analysis. Reg Cancer Treat 1995;8:83-87.
29. Thompson JF, Kam PC, Ramzan I, Yau DF: Pharmacokinetics of melphalan during isolated limb infusion for melphalan. Reg Cancer Treat 1996;9:13-16.
30. Parsons PG, Carter FB, Morrison L, Mary SR: Mechanism of melphalan resistance development in human melanoma cells. Cancer Res 1981;41:1525-1534.
31. Love BR: The tourniquet. Aust NZ J Surg 1978;48:66-71.
32. DeVita VT: Principles of chemotherapy. In DeVita VT, Helman S, Rosenberg SA (eds): "Cancer: principles and practice of oncology". 3rd ed. Philadelphia: Lippincott; 1989. p. 270-278.
33. Jansen RF, Van Geel BN, van der Zee J, et al: Intractable cutaneous non-Hodgkins lymphoma of the lower limb. Complete remission after sequential regional isolated hyperthermic perfusion and perfusion with I-phenylalanine-mustard (melphalan, L-PAM). Cancer 1989;64:392-395.
34. Tannock IF: Principles of cell proliferation cell kinetics. In DeVita VT, Helman S, Rosenberg SA (eds): "Cancer: principles and practice of oncology". 3rd ed. Philadelphia: Lippincott; 1989. p. 3-13.
35. Kroon BB, Klaase JM, van Geel BN, et al: Result of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993;29A:325-328.
36. Klaase JM, Kroon BB, van Geel AN, et al: A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1989;71:2990-2994.
37. Klaase JM, Kroon BB, Van Geel AN, et al: Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Melanoma Res 1994;4:(Suppl 1)13-16.
38. Fiorentini G, Poddie D, Graziani G: Hypoxic isolated limb perfusion with mitomycin C in locally recurrent melanoma and sarcoma: results of a phase II study. Reg Cancer Treat 1995;8:135-139.